VC-backed Stealth BioTherapeutics goes public
Stealth BioTherapeutics, a biotech company focused on developing new treatments involving mitochondrial dysfunction, has raised $78 million for its IPO of 6.5 million shares at $12 per share. The stock began trading February 15, 2019 on the NASDAQ under the ticker symbol "MITO." Jefferies LLC, Evercore Group LLC and BMO Capital Markets Corp are the lead underwriters. Stealth pre-IPO backers include Nan Fung Technology’s Pivotal Beta, Atlantis Investment Management, BVCF Management, CMBC Capital Holdings, Kingdon Capital, Ocean Equity Partners, Sagamore Investments and Morningside Ventures.
15 February 2019•3 mins read
